Gelteq Preclinical Results Show Increased Medicinal Cannabinoid Absorption with Oral Gel Platform
MELBOURNE, Australia – Gelteq Limited, a pioneering developer of advanced gel-based oral delivery systems, has announced compelling positive results from its recent preclinical study. The research confirmed that Gelteq’s proprietary oral gel platform significantly enhances the absorption and bioavailability of cannabidiol (CBD) compared to an existing FDA-approved oil-based product.
in CBD Bioavailability, coupled with higher peak exposure, despite using a much lower CBD concentration than the comparative oil-based product. This demonstrates the platform’s superior efficiency for lipophilic cannabinoid molecules.
These preliminary results underscore the transformative potential of Gelteq’s platform to revolutionize how medicinal cannabis is delivered, experienced, and utilized by patients globally. The enhanced efficiency also creates a clear pathway for an expedited market launch in Australia via the Special Access Scheme (SAS), paving the way for international expansion.
Traditional medicinal cannabis products, such as oils and vapes, often present numerous challenges, including inconsistent absorption, variable dosing, slow onset, unpleasant taste, and inhalation risks. Gelteq’s oral gel platform directly addresses these limitations, offering a safer, more predictable, and highly convenient alternative.
Precise Dosing & Consistency
Pre-measured doses eliminate the need for droppers and dependence on food timing, ensuring consistent therapeutic effects.
Improved Bioavailability
Higher absorption means patients may achieve desired outcomes with lower doses, reducing exposure to unnecessary compounds.
Non-Invasive & Safe
Offers a safer alternative to vaping, alleviating concerns about respiratory irritation, and is ideal for pediatric, geriatric, and palliative-care patients.
The company anticipates that these preclinical results will unlock significant global commercial opportunities. The medicinal cannabis market is rapidly expanding, with product differentiation increasingly driven by innovation in delivery systems. Gelteq’s platform offers a distinct advantage, enabling cannabis producers to elevate their offerings beyond conventional oils or tinctures.
- Direct Partnerships: The study outcomes facilitate direct collaboration with medicinal cannabis companies, potentially accelerating licensing, white-label manufacturing, and co-development.
- Broad Applications: The platform is suitable for a wide range of cannabinoid-based products, including CBD, THC, balanced ratios, minor cannabinoids, and nutraceutical combinations.
- Accelerated Market Entry (Australia): The Australian SAS program enables rapid product launches, generating early revenues and establishing a strong market presence for international growth.
By enabling a simpler and more effective cannabinoid administration, Gelteq’s oral gel platform is poised to define the next generation of medicinal cannabis products, meticulously designed around patient needs and modern clinical expectations.
